🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

227 results for “Shi” Clear

  1. 608 Dose A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ankylosing Spondylitis

    phase 2 small molecule active

    1 trial

  2. 609A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  3. 610 100mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Asthma

    phase 2 small molecule active

    1 trial

  4. 611 150mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule completed

    1 trial

  5. 611 300 mg Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  6. 611 Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule completed

    1 trial

  7. 626

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  8. 627

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  9. 68Ga-Pentixafor

    Peking University Third Hospital

    Cushing s Syndrome

    phase 2 small molecule active

    1 trial

  10. A Phase II Multicenter, Open-Label Study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients with Duchenne Muscular Dystrophy (SHIELD DMD)

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy (DMD)

    phase 2 other active

    1 trial

  11. A Phase II, multi-site, open-label, dose-titration trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of Lu AG13909 in adults with Cushing’s disease

    H. Lundbeck A/S

    Cushing's Disease

    phase 2 other active

    1 trial

  12. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial

  13. CORT125134

    CORCEPT THERAPEUTICS INC

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial

  14. CPGJ602

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  15. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced NSCLC

    phase 2 small molecule terminated

    1 trial

  16. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  17. CT053PTSA

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Renal Cell Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  18. Camrelizumab Plus Apatinib

    Nanjing Zenshine Pharmaceuticals

    Unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  19. Cefiderocol

    Shionogi B.V.

    Gram-negative Bacterial Infections

    phase 2 small molecule completed

    1 trial

  20. Clifutinib Besylate

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule active

    1 trial

  21. Dexmedetomidine injection

    Sana Biotechnology

    Post Spinal Shivering

    phase 2 small molecule active

    1 trial

  22. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis B

    phase 2 small molecule completed

    3 trials

  23. GLS4

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HBV Infection

    phase 2 small molecule completed

    1 trial

  24. HEC110114 tablet

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Hepatitis C

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources